Profile data is unavailable for this security.
About the company
Inter Pharma Public Company Limited is a Thailand-based biopharmaceutical company. The Company is engaged in the import, manufacture and distribution of drug, dietary supplement products for humans and animals. Its segment includes Human healthcare, Animal healthcare, and Hospital. It provides animal health care products and human health care products. It develops and delivers health products that use biotechnology for disease prevention, longevity, and anti-aging. Its human health care products include pharmaceuticals, nutraceuticals / health supplements, cosmeceuticals, functional foods and drinks and others. Its animal health care products include medicine companion animal, neutraceuticals companion animal, shampoo, vaccine and immunoglobulin, premium pet food, ear cleaner, teeth cleaner and pee pad. Its products include ProLivo, Pronac Mood, Probac 7 and others. It also offers pet foods for dogs and cats. Its subsidiaries include Inter Vetta Co., Ltd., and Modern Pharma Co., Ltd.
- Revenue in THB (TTM)1.79bn
- Net income in THB26.52m
- Incorporated2019
- Employees282.00
- LocationInter Pharma PCL140/9 ITF Tower 9th FloorSilom Road, SuriyawongBANGKOK 10500ThailandTHA
- Phone+66 26340225
- Fax+66 26340135
- Websitehttps://www.interpharma.co.th/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RaQualia Pharma Inc | 498.17m | -57.92m | 2.94bn | 67.00 | -- | 2.14 | -- | 5.90 | -11.72 | -11.72 | 100.79 | 277.21 | 0.247 | 2.76 | 3.03 | 32,526,720.00 | -2.87 | 2.13 | -3.18 | 2.26 | 88.70 | 88.49 | -11.63 | 5.32 | 3.53 | -- | 0.4031 | 0.00 | -34.85 | 20.62 | -144.74 | -- | 0.0967 | -- |
| Bangkok Lab and Cosmetic PCL | 1.43bn | 156.29m | 2.94bn | 698.00 | 18.04 | 1.82 | 13.63 | 2.05 | 0.2717 | 0.2717 | 2.50 | 2.69 | 0.8267 | 2.44 | 4.35 | 2,054,923.00 | 9.32 | 6.01 | 14.01 | 13.28 | 31.30 | 27.33 | 11.28 | 5.68 | 3.48 | 9.80 | 0.1233 | -- | 8.50 | 17.54 | 15.65 | 51.84 | 19.54 | -- |
| Inter Pharma PCL | 1.79bn | 26.52m | 2.99bn | 282.00 | 112.73 | 1.55 | 22.57 | 1.67 | 0.0438 | 0.0438 | 2.96 | 3.19 | 0.5961 | 3.31 | 4.90 | -- | 1.05 | 5.54 | 1.34 | 7.20 | 36.43 | 42.85 | 1.75 | 8.01 | 1.71 | 2.72 | 0.1529 | 33.15 | 16.93 | 41.18 | -57.28 | 11.34 | 73.30 | -- |
| ReproCell Inc | 554.75m | -7.18m | 2.99bn | 96.00 | -- | 1.56 | 2,297.01 | 5.39 | -0.3466 | -0.3466 | 28.34 | 93.45 | 0.2788 | 5.41 | 5.60 | 25,279,340.00 | -0.3609 | -7.35 | -0.3932 | -8.00 | 46.19 | 39.83 | -1.29 | -27.16 | 10.54 | -- | 0.00 | -- | -17.83 | 17.39 | 89.71 | -- | 13.27 | -- |
| Recce Pharmaceuticals Ltd | 167.04m | -277.46m | 3.00bn | -- | -- | 228.80 | -- | 17.96 | -0.0637 | -0.0637 | 0.0385 | 0.0026 | 1.68 | -- | 52.84 | -- | -279.04 | -110.82 | -985.91 | -139.61 | -- | -- | -166.11 | -391.79 | -- | -24.07 | 0.2712 | -- | 39.53 | 27.79 | -19.03 | -- | -26.31 | -- |
| Sakar Healthcare Ltd | 676.43m | 51.48m | 3.02bn | 297.00 | 56.60 | 2.61 | 23.08 | 4.47 | 5.57 | 5.57 | 73.21 | 120.61 | 0.423 | 3.88 | 7.13 | -- | 3.22 | 5.26 | 3.81 | 6.28 | 45.43 | 44.13 | 7.60 | 10.12 | 0.743 | 2.68 | 0.2322 | -- | 14.99 | 17.58 | -8.53 | 11.76 | 19.05 | -- |
| Biome Australia Ltd | 251.14m | -70.24m | 3.06bn | 30.00 | -- | 57.26 | -- | 12.18 | -0.0141 | -0.0141 | 0.0506 | 0.0101 | 1.37 | 1.93 | 6.04 | 341,434.70 | -38.27 | -- | -74.60 | -- | 61.29 | -- | -27.97 | -- | 0.9514 | -15.92 | 0.4032 | -- | 73.58 | -- | 32.20 | -- | -- | -- |
| Nectar Lifesciences Ltd | 7.44bn | 22.03m | 3.06bn | 1.59k | 134.48 | 0.6487 | 10.56 | 0.4115 | 0.23 | 0.23 | 79.16 | 47.68 | 0.7697 | 1.74 | 5.12 | -- | 0.228 | -0.2956 | 0.3969 | -0.541 | 28.68 | 18.39 | 0.2963 | -0.4052 | 0.5907 | 1.06 | 0.3728 | -- | 10.63 | -9.54 | 120.65 | -36.29 | -5.06 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Kasikorn Asset Management Co., Ltd.as of 09 May 2023 | 6.78m | 1.40% |
| TISCO Asset Management Co., Ltd.as of 28 Dec 2023 | 4.41m | 0.91% |
| Dimensional Fund Advisors LPas of 06 Jun 2024 | 325.32k | 0.07% |
